Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Oncol Pharm Pract ; 28(4): 904-909, 2022 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-35179058

RESUMEN

INTRODUCTION: Pediatric and adolescent oncology patients admitted to receive chemotherapy are at risk for drug-drug interactions (DDI). While adult literature has quoted this risk to be as high as 95% of encounters, the literature in pediatrics is limited. This is a single-center, retrospective chart review of DDI in hospitalized pediatric oncology patients. METHODS: All patients admitted to Texas Children's Hospital for chemotherapy were included. Medications ordered during the hospitalization were evaluated by Lexicomp® Drug Interactions Tool. Interactions classified as D or X or interactions rated a C including a chemotherapeutic agent were independently reviewed by three clinicians for clinical relevance. Medications associated with central nervous system (CNS) depression or QTc prolongation were counted separately. RESULTS: Of 100 admissions evaluated, 100% had a flagged interaction. There were a total of 12 X-rated interactions, 8 D-rated interactions, and 12 C-rated interactions with a chemotherapeutic agent found to be clinically relevant. Thirty-three percent of admissions had 4 or more QTc prolonging medications ordered. Twenty-four percent of admissions had 3 or more prescribed CNS depressants. In total 49% of admissions were found to have at least 1 clinically-significant DDI. CONCLUSIONS: This study exemplifies the risk of drug-drug interactions in children and young adults admitted to the hospital for chemotherapy. We demonstrated a high rate of flagged interactions with about half of admissions found to have a potentially clinically-significant DDI. Concomitant use of multiple QTc prolonging and CNS depressant medications was also prevalent, indicating a need to evaluate monitoring practices.


Asunto(s)
Antineoplásicos , Neoplasias , Pediatría , Adolescente , Antineoplásicos/efectos adversos , Niño , Interacciones Farmacológicas , Humanos , Oncología Médica , Neoplasias/tratamiento farmacológico , Estudios Retrospectivos , Adulto Joven
3.
Clin J Gastroenterol ; 14(1): 88-91, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33165831

RESUMEN

Primary gastric Burkitt's lymphoma (BL) is rare in the pediatric population. Furthermore, the association of Burkitt's lymphoma with Helicobacter pylori is not well defined. We report a case of primary gastric Burkitt's lymphoma associated with Helicobacter pylori diagnosed in a pediatric patient. This diagnosis was made with the aid of endoscopic ultrasound (EUS)-guided fine-needle biopsy (FNB). This is one of the first pediatric cases of EUS-guided FNB for the diagnosis of H. pylori-associated gastric BL.


Asunto(s)
Linfoma de Burkitt , Infecciones por Helicobacter , Helicobacter pylori , Neoplasias Gástricas , Adolescente , Linfoma de Burkitt/diagnóstico por imagen , Linfoma de Burkitt/microbiología , Femenino , Infecciones por Helicobacter/complicaciones , Humanos , Neoplasias Gástricas/diagnóstico por imagen , Neoplasias Gástricas/microbiología , Ultrasonografía Intervencional
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA